CEL-SCI Co. (NYSE:CVM) to Post FY2024 Earnings of ($0.51) Per Share, Zacks Small Cap Forecasts

CEL-SCI Co. (NYSE:CVM) – Investment analysts at Zacks Small Cap reduced their FY2024 EPS estimates for shares of CEL-SCI in a note issued to investors on Monday, April 15th. Zacks Small Cap analyst J. Vandermosten now expects that the company will post earnings of ($0.51) per share for the year, down from their previous estimate of ($0.48). The consensus estimate for CEL-SCI’s current full-year earnings is ($0.48) per share.

CEL-SCI (NYSE:CVM) last posted its quarterly earnings data on Wednesday, February 14th. The company reported ($0.14) earnings per share for the quarter.

Separately, StockNews.com cut shares of CEL-SCI from a “hold” rating to a “sell” rating in a report on Friday, March 15th.

CEL-SCI Trading Down 1.3 %

NYSE CVM traded down $0.02 on Wednesday, hitting $1.50. 133,503 shares of the stock were exchanged, compared to its average volume of 303,426. CEL-SCI has a 52-week low of $1.04 and a 52-week high of $3.23. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.26 and a quick ratio of 0.78. The company has a market capitalization of $80.97 million, a price-to-earnings ratio of -2.24 and a beta of 1.29. The company’s 50-day moving average price is $2.06 and its two-hundred day moving average price is $2.18.

Institutional Investors Weigh In On CEL-SCI

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of CEL-SCI by 9.4% in the 4th quarter. Vanguard Group Inc. now owns 2,079,624 shares of the company’s stock valued at $5,657,000 after purchasing an additional 178,478 shares during the last quarter. Renaissance Technologies LLC acquired a new position in CEL-SCI during the 1st quarter worth $3,037,000. BlackRock Inc. lifted its position in CEL-SCI by 2.3% during the 2nd quarter. BlackRock Inc. now owns 753,702 shares of the company’s stock worth $1,816,000 after acquiring an additional 16,724 shares during the last quarter. Millennium Management LLC lifted its position in CEL-SCI by 212.6% during the 2nd quarter. Millennium Management LLC now owns 572,700 shares of the company’s stock worth $2,577,000 after acquiring an additional 389,513 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in CEL-SCI by 10.8% during the 2nd quarter. Geode Capital Management LLC now owns 423,501 shares of the company’s stock worth $1,021,000 after acquiring an additional 41,400 shares during the last quarter. Institutional investors and hedge funds own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.